drugset / Trial / NCT03390036

Study of Cingal for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow up

NCT03390036

Phase 3 Completed 526 enrolled Anika Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

Extension study to Cingal 16-02 to obtain 39-week safety and efficacy follow-up data

Timeline

Start
2017-12-07
Primary completion
2018-07-30
Completion
2018-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Hyaluronic Acid Other / unclassified 88 mg Other
Comparator Triamcinolone Hexacetonide Other / unclassified 18 mg Other
Comparator Triamcinolone Hexacetonide Other / unclassified 20 mg Other

Indications